Literature DB >> 23100324

Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).

Jeannette Hübener1, Jonasz Jeremiasz Weber, Claudia Richter, Lisa Honold, Andreas Weiss, Fabronia Murad, Peter Breuer, Ullrich Wüllner, Peter Bellstedt, Francois Paquet-Durand, Jiro Takano, Takaomi C Saido, Olaf Riess, Huu Phuc Nguyen.   

Abstract

Spinocerebellar ataxia type 3 (SCA3) is pathologically characterized by the formation of intranuclear aggregates which contain ataxin-3, the mutated protein in SCA3, in a specific subtype of neurons. It has been proposed that ataxin-3 is cleaved by proteolytic enzymes, in particular by calpains and caspases, eventually leading to the formation of aggregates. In our study, we examined the ability of calpains to cleave ataxin-3 in vitro and in vivo. We demonstrated in cell culture and mouse brain homogenates that cleavage of overexpressed ataxin-3 by calpains and in particular by calpain-2 occur and that polyglutamine expanded ataxin-3 is more sensitive to calpain degradation. Based on these results, we investigated the influence of calpains on the pathogenesis of SCA3 in vivo. For this purpose, we enhanced calpain activity in a SCA3 transgenic mouse model by knocking out the endogenous calpain inhibitor calpastatin. Double-mutant mice demonstrated an aggravated neurological phenotype with an increased number of nuclear aggregates and accelerated neurodegeneration in the cerebellum. This study confirms the critical importance of calcium-dependent calpain-type proteases in the pathogenesis of SCA3 and suggests that the manipulation of the ataxin-3 cleavage pathway and the regulation of intracellular calcium homeostasis may represent novel targets for therapeutic intervention in SCA3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100324     DOI: 10.1093/hmg/dds449

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  29 in total

Review 1.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

2.  Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Authors:  Meike Diepenbroek; Nicolas Casadei; Hakan Esmer; Takaomi C Saido; Jiro Takano; Philipp J Kahle; Ralph A Nixon; Mala V Rao; Ronald Melki; Laura Pieri; Stefan Helling; Katrin Marcus; Rejko Krueger; Eliezer Masliah; Olaf Riess; Silke Nuber
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

Review 3.  Calpain-2 as a therapeutic target for acute neuronal injury.

Authors:  Yubin Wang; Xiaoning Bi; Michel Baudry
Journal:  Expert Opin Ther Targets       Date:  2017-11-28       Impact factor: 6.902

4.  Effects of the enlargement of polyglutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins.

Authors:  Jingran Wen; Daniel R Scoles; Julio C Facelli
Journal:  J Biomol Struct Dyn       Date:  2016-05-20

5.  Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.

Authors:  Maxinne Watchon; Kristy C Yuan; Nick Mackovski; Adam J Svahn; Nicholas J Cole; Claire Goldsbury; Silke Rinkwitz; Thomas S Becker; Garth A Nicholson; Angela S Laird
Journal:  J Neurosci       Date:  2017-07-07       Impact factor: 6.167

6.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

7.  Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Katiuska Luna-Cancalon; Svetlana Fischer; Naila S Ashraf; Michelle Ouyang; Rahil M Dharia; Lucas Martin-Fishman; Yemen Yang; Vikram G Shakkottai; Beverly L Davidson; Edgardo Rodríguez-Lebrón; Henry L Paulson
Journal:  Mol Ther       Date:  2013-06-14       Impact factor: 11.454

8.  Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.

Authors:  Jonasz J Weber; Eva Haas; Yacine Maringer; Stefan Hauser; Nicolas L P Casadei; Athar H Chishti; Olaf Riess; Jeannette Hübener-Schmid
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

9.  Calpain 5 is highly expressed in the central nervous system (CNS), carries dual nuclear localization signals, and is associated with nuclear promyelocytic leukemia protein bodies.

Authors:  Ranjana Singh; M Kathryn Brewer; Charles B Mashburn; Dingyuan Lou; Vimala Bondada; Brantley Graham; James W Geddes
Journal:  J Biol Chem       Date:  2014-05-16       Impact factor: 5.157

10.  Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.

Authors:  Y X Li; O C M Sibon; P F Dijkers
Journal:  J Neuroinflammation       Date:  2018-09-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.